A novel biomarker called ADMA/SDMA is an independent predictor of heart attack risk and may also identify patients with diabetes, pre-diabetes or kidney disease, according to recent peer-reviewed studies. The ADMA/SDMA biomarker blood test, now available through Cleveland HeartLab (CHL), measures levels of asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA). Elevated levels of these biomarkers can signal damage to the …
